Home / Politics / NEURALSTEM SPENDS US$3 MLN ON ISCHEMIC STROKE TREATMENT STUDY

NEURALSTEM SPENDS US$3 MLN ON ISCHEMIC STROKE TREATMENT STUDY

KUALA LUMPUR, Malaysia Neuralstem Inc will allocate US$3 million (RM12.15 million) toward Phase 2 clinical trial evaluating neural stem cell candidate, NSI-566 as a potential treatment for ischemic stroke. (1US$ = RM4.05)

Ischemic stroke is the most common type of stroke, occur as a result of an obstruction within a blood vessel supplying blood to the brain. Approximately 15 million people worldwide suffer stroke 87 per cent are ischemic strokes, a statement said.

Chief Scientific Officer of Neuralstem, Dr. Karl Johe said the Phase 2 study will be a randomized, double-blind, controlled study, based on the encouraging results from the open-label Phase 1 safety study.

It is intended to further test the safety and efficacy of NSI-566 to reverse paralysis in stroke patients with half of their body partially paralyzed, he added.

The trial will be taking place at Bayi Brain Hospital in Beijing, China, commencing on Aug 1 with Executive Vice President of Asia Operations of Suzhou Neuralstem Ltd, Dr. James Li managing the clinical trial.

Source: NAM News Network

Check Also

53 Lao Women and Girls Rounded Up in Karaoke Bar Raid in Southern Thailand

Police and military personnel rounded up and detained 53 Laotians50 women and three girls who were allegedly employed as sex workersduring raids on karaoke bars in southern Thailand's Narathiwat province, authorities said Friday.The Thursday night raid...